1. Introduction {#sec1}
===============

Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter within the eye and brain \[[@B1], [@B2]\]. There are two main classes of GABA receptors: GABA~A~ receptors are ligand-gated ion channels (ionotropic receptors), whereas GABA~B~ receptors are G protein-coupled receptors (metabotropic receptors) \[[@B3], [@B4]\]. GABA~B~ receptors are comprised of two principal heterodimeric subunits, GABA~B1~ and GABA~B2~. GABA~B~ receptors via Gi/o proteins interact with neuronal inwardly rectifying potassium and voltage-gated calcium channels and when activated mediate slow synaptic inhibition \[[@B5]\].

In eyes, GABA~B~ receptors have been identified within the retina on photoreceptors, bipolar cells, amacrine cells, and ganglion cells \[[@B1], [@B6]\] and recently detected in chick retinal pigment epithelium \[[@B7]\]. In the retina, GABA~B~ receptors have been shown to modulate calcium currents in isolated goldfish retinal ganglion cells \[[@B8]\], modify acetylcholine and glycine release from amacrine cells in the rabbit retina \[[@B9]\], control arteriolar diameter in rat retinal whole-mounts \[[@B10]\], regulate chick retinal calcium waves during retinal development \[[@B11]\], and modify form-deprivation myopia (FDM) in chick eyes \[[@B12]\]. Although usually considered an inhibitory transmitter, the GABA~B~ receptor agonist baclofen facilitates the L-type calcium channel while inhibiting the N-type calcium current in isolated spiking retinal neurons from salamander retina \[[@B13]\].

CGP46381 is a water soluble GABA~B~ receptor antagonist of 219.26 molecular weight, IC~50~ of 4.9 *μ*M \[[@B14]\]. GABA~B~ antagonists alter neuronal brain activity; for example, CGP 36742 and CGP 51176 exhibit antidepression like effects in the forced swim test in mice \[[@B15]\] and SGS742 (CGP 36742) facilitates memory and cognition \[[@B16]\] in rats. The GABA~B~ antagonist CGP46381 is reported to antagonize the diminishing response to repeated auditory stimuli in rat hippocampus \[[@B17]\], inhibit suppression of hippocampal long-term potentiation and impair spatial learning in rats \[[@B18]\], stimulate spontaneous locomotor activity in mice \[[@B19]\], modify the contrast of the sensory input map in the olfactory receptor neuron terminals in mice \[[@B20]\], show proconvulsant activity of cortical epileptic after discharges in developing rat brain \[[@B21]\], and suppress absence seizures in the lethargic mutant mouse and rat models \[[@B22], [@B23]\].

CGP46381 has been shown to inhibit FDM in the chick model \[[@B12]\]. Other GABA antagonists shown to alter eye growth in chick include GABA~A~ (SR95531 \[[@B12]\], bicuculline \[[@B24]\]) and GABA~AOr~ (cis- and trans-3-ACPBPA \[[@B25]\] and TPMPA \[[@B12], [@B24], [@B26]\]) receptor antagonists. Additional GABA~B~ receptor antagonists shown to inhibit myopia in chick include SCH50911 and 2OH-saclofen \[[@B12]\]. Among all the GABA agents shown to inhibit myopia in chicks, cis- and trans-3-ACPBPA, TPMPA, and CGP46381 are the most effective \[[@B12], [@B25], [@B26]\]. Guinea pigs are a very useful mammalian eye growth model \[[@B27]--[@B30]\]. The GABA~AOr~ receptor antagonist TPMPA has been reported to inhibit FDM in guinea pigs \[[@B31], [@B32]\]. The aim was to determine whether CGP46381 (GABA~B~ antagonist) inhibits FDM in guinea pigs.

2. Methods {#sec2}
==========

2.1. Treatments: FDM and Subconjunctival Injections {#sec2.1}
---------------------------------------------------

Thirty 14-day-old pigmented guinea pigs (Cavia porcellus) were obtained from Beijing Keyu Animal Centre (Beijing, China). Animals were reared under a 12-hour light/12-hour dark cycle (the light level was 1000 lux at the cage floor) in the animal facility. All guinea pigs had free access to food and water, and fresh cabbage was provided twice daily. Treatment and care of animals were conducted according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Twenty-four guinea pigs had monocular visual deprivation induced using a diffuser (random application, using velcro and tape, to the right or left eye) for 11 days (day 14 to 25) as previously described \[[@B29], [@B30], [@B33]\]. The deprived eyes were treated with daily subconjunctival injections (100 *μ*L) of either 2% CGP46381, 0.2% CGP46381, or saline or received no injection (*n* = 6). The fellow eye was left untreated. Another six animals received no treatment to either eye.

The concentration of CGP46381 was based on published work involving the chick myopia model and the physicochemical characteristics of CGP46381. Stone and coauthors \[[@B12]\] reported that intravitreal injection of CGP46381, at doses ranging from 1 *μ*g to 200 *μ*g, significantly inhibited the development of FDM and the associated vitreous chamber and axial elongation in chicks; the maximal antimyopia effect occurred at doses above 100 *μ*g. Subconjunctival application requires the injected agent to penetrate the sclera if it is to have intraocular effects; Dong and coauthors \[[@B28]\] calculated that only 1/10^4^ of the applied dose reached the inside of the guinea pig eye. The maximum water solubility of CGP46381 is 100 mM (equivalent to 2.2%); to avoid solubility issues 2% was chosen as the maximum concentration. Thus concentrations of 0.2% (100 *μ*L contains 200 *μ*g) and 2% were used.

CGP46381 (Tocris, Glasgow, UK) was dissolved in injectable saline and stored at −80°C until required. Subconjunctival injections were performed as previously described \[[@B28]\] after removal of the diffuser. The injection was performed under anaesthesia (2% isoflurane in oxygen; 26-gauge needle) once daily (9--11 AM) in a timely manner (less than 2 min) for 11 days. The injection site was the peripheral bulbar conjunctiva. After the injection, a drug bolus was observed under the conjunctiva. The diffuser was replaced immediately following the injection.

2.2. Measurements: Refraction, Vitreous Chamber Depth, and Axial Length {#sec2.2}
-----------------------------------------------------------------------

At the start and the end of the treatment refraction and eye length measurements were made. Refractive errors were measured using streak retinoscopy in awake animals following cycloplegia (3 drops of 1% cyclopentolate hydrochloride; Alcon, Fort Worth, TX) as previously described \[[@B28], [@B30]\]. Three readings were made along the horizontal and vertical meridians and the average of these, the spherical equivalent refraction (SER), used in subsequent data analyses.

Axial length (AL) and vitreous chamber depth (VCD) were measured using an A-scan ultrasonography (Suoer, 10 MHz; Tianjin, China) under anaesthesia (2% isoflurane in oxygen). The assumed conduction velocities were 1540 m/s \[[@B30]\]. The AL was defined as the distance between the front of the cornea and the inner limiting membrane of the retina. VCD was defined as the distance from the back of the lens to the inner retinal surface. Three ultrasound measurements comprising independent alignments of the probe were averaged and used in data analysis.

2.3. Data Analysis {#sec2.3}
------------------

Data were analyzed using the GraphPad Prism 5 (Version 5.01, GraphPad Software, Inc., USA). SER, VCD, and AL of treated and untreated eyes of guinea pigs within the same treatment group were analyzed using paired *t*-tests. The interocular differences in SER, AL, and VCD of eyes of guinea pigs in different treatment groups were analyzed using one-way ANOVA and Dunnett\'s post hoc test. Both the within group and between group differences were defined as significant at *P* \< 0.05.

3. Results {#sec3}
==========

At commencement of the experiment there were no significant differences in SER, AL, or VCD of treated and untreated eyes in each group (*P* \> 0.05, paired *t*-test). There were also no significant differences in SER, AL, or VCD of eyes across different treatment groups (*P* \> 0.05, one-way ANOVA). Similarly at the end of the experiment, there were no significant differences in SER, AL, or VCD of untreated eyes across the groups (*P* \> 0.05, one-way ANOVA).

At the end of the treatment period form-deprived eyes had developed relative myopia (*P* \< 0.05, paired *t*-test). The interocular differences (treated minus untreated eye data) in SER were −0.04 ± 0.17 D in the normal group (neither eye treated), −4.79 ± 0.60 D in the FDM with no injection group, −4.33 ± 0.67 D in the FDM + saline group, −3.92 ± 0.72 D in the FDM + 0.2% CGP46381 group, and −1.08 ± 0.40 D in the FDM + 2% CGP46381 group ([Figure 1](#fig1){ref-type="fig"}). The amount of myopia induced was significantly affected by the drug treatment (one-way ANOVA, *F* = 74.61, *P* \< 0.0001). Myopia was significantly less in the FDM + 2% CGP46381 group compared to that in FDM + saline group (Dunnett\'s post hoc, *P* \< 0.01). There was no significant difference in relative myopia between the FDM + 0.2% CGP46381 group and the FDM + saline group (Dunnett\'s post hoc, *P* \> 0.05). These data show that 2% CGP46381 subconjunctival injections inhibit FDM.

At the end of the treatment period the interocular differences in AL were −0.00 ± 0.01 mm in the normal group, 0.14 ± 0.02 mm in the FDM with no injection group, 0.13 ± 0.02 mm in the FDM + saline group, 0.11 ± 0.02 mm in the FDM + 0.2% CGP46381 group, and 0.03 ± 0.01 mm in the FDM + 2% CGP46381 group ([Figure 2](#fig2){ref-type="fig"}). The amount of AL elongation was significantly affected by the drug treatment (one-way ANOVA, *F* = 58.38, *P* \< 0.0001). The amount of AL elongation of the form-deprived eyes in the FDM + 2% CGP46381 group was significantly less than that in FDM + saline group (Dunnett\'s post hoc, *P* \< 0.01). There was no significant difference in AL elongation of form-deprived eyes of the FDM + 0.2% CGP46381 and FDM + saline groups (Dunnett\'s post hoc: 0.2% CGP46381 versus saline, *P* \> 0.05).

At the end of treatment the interocular differences in VCD were −0.00 ± 0.01 mm in the normal group, 0.08 ± 0.02 mm in the FDM with no injection group, 0.08 ± 0.01 mm in the FDM + saline group, 0.07 ± 0.01 mm in the FDM + 0.2% CGP46381 group, and 0.02 ± 0.01 mm in FDM + 2% CGP46381 group ([Figure 3](#fig3){ref-type="fig"}). The amount of VCD elongation was significantly affected by the drug treatment (one-way ANOVA, *F* = 43.50, *P* \< 0.0001). The VCD elongation in form-deprivation eyes in the FDM + 2% CGP46381 group was significantly reduced compared to the FDM + saline group (one-way ANOVA and Dunnett\'s test: 2% CGP46381 versus saline, *P* \< 0.01). There was no significant difference in VCD elongation in form-deprivation eyes of the FDM + 0.2% CGP46381 group and the FDM + saline group (one-way ANOVA and Dunnett\'s test: 0.2% CGP46381 versus saline, *P* \> 0.05). These data show that 2% CGP46381 subconjunctival injections inhibit the VCD elongation in FDM ([Figure 3](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

We found that CGP46381, a GABA~B~ receptor antagonist, which inhibits experimental myopia development in chick models \[[@B12]\], also inhibits FDM in guinea pigs. Subconjunctival injections of 2% CGP46381 significantly inhibited the myopic shift and the elongation of AL and VCD. These data show that CGP46381 not only inhibits FDM in an avian model but also inhibits FDM in a mammalian (guinea pig) model.

Stone and coauthors \[[@B12]\] reported that intravitreal injection of CGP46381 inhibited FDM in chicks; the minimum effective dose was 1 *μ*g per day. Here we found that subconjunctival injection of CGP46381 inhibits FDM in guinea pigs; the effective dose was 100 *μ*L of 2% CGP46381 (2 mg per day), whereas the lower dose, 100 *μ*L of 0.2% CGP46381 (200 *μ*g per day), did not inhibit myopia. These data show that the effective antimyopia dose of CGP46381 applied via subconjunctival injection in guinea pigs is approximately 2000 times higher than that for intravitreal injection in chicks. These data are consistent with only 1/10^4^ of the applied subconjunctival dose reaching the vitreous chamber \[[@B26]\]. Leech and coauthors report that daily subconjunctival injections of pirenzepine were significantly less effective at inhibiting myopia than were intravitreal injections \[[@B34]\]. The concentration of CGP46381 found here to inhibit myopia can now be used in future investigations utilizing subconjunctival injections.

We previously reported that the GABA~AOr~ receptor antagonist TPMPA inhibits FDM in guinea pigs \[[@B32]\] and here we report that the GABA~B~ receptor antagonist CGP46381 has similar antimyopia effects. The maximal doses tested in both cases were similarly effective: 2% CGP46381 (91 mM) inhibited \~70% of the FDM and 1% TPMPA (62 mM) inhibited \~80% (*P* = 0.493). The effects of 2% CGP46381 and 1% TPMPA on the AL and VCD elongation were also similar (*P* = 0.200 and *P* = 0.243, resp.). The lower dose tested, 0.2% CGP46381 (9 mM), did not inhibit FDM whereas 0.3% TPMPA (19 mM) inhibited \~30%. The 0.3% dose of TPMPA was more effective than 0.2% CGP46381 at inhibiting myopia (*P* = 0.047) and VCD elongation (*P* = 0.012), while the degree of AL elongation was similar (*P* = 0.066). Stone and coauthors \[[@B12]\] reported that the minimum dose for TPMPA inhibiting FDM in chicks is 0.1 *μ*g and 1 *μ*g for CGP46381, and when a higher dose was used (e.g., 100 ug), the antimyopia effects for TPMPA and CGP46381 were similar. Our results in guinea pigs show correspondence to the results in chicks.

In this study, we found that CGP46381 inhibits FDM in guinea pigs, but the potential targets and possible mechanisms are not clear. GABA~B~ receptors have been detected in the retina \[[@B1]\] and RPE \[[@B7]\], which suggested that the retina and RPE would be the potential targets for CGP46381 inhibiting myopia. Sclera \[[@B35]\], choroid \[[@B36]\], RPE \[[@B37]\], and retina \[[@B38]\] are all implicated in myopia development, and the sclera determines the ocular size. How CGP46381 contacts with the GABA~B~ receptors in the retina and RPE and how the signals are then translated to the sclera to inhibit the eye elongation and myopia development require further investigation.

Several other kinds of neurotransmitter agents inhibit experimental myopia in a variety of animal models, including the muscarinic acetylcholine receptor nonspecific antagonist atropine (in chicks \[[@B39]\], mice \[[@B40]\], and monkeys \[[@B41]\]), the M1 receptor antagonist pirenzepine (in chicks \[[@B34]\], guinea pigs \[[@B27]\], and monkeys \[[@B41]\]), the M4 muscarinic antagonist MT-3 (in chicks \[[@B42]\] and tree shrews \[[@B43]\]), the dopamine receptor agonist, and apomorphine (in chicks \[[@B33], [@B44]\], guinea pigs \[[@B28]\], and monkeys \[[@B45]\]). Thus GABA must be involved in a complicated eye growth pathway involving many retinal cells and associated transmitters.

In summary, we found that subconjunctival injection of the GABA~B~ receptor antagonist CGP46381 can effectively inhibit FDM in guinea pigs. Whether CGP46381 inhibits myopia in the other animal models and humans requires further investigation. The potential targets and possible mechanisms via which CGP46381 inhibits myopia remain unexplored.
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![Effect of CGP46381 on spherical equivalent refraction (SER). Interocular differences (mean ± SD) in SER varied significantly with treatment (*P* \< 0.0001). Compared to saline, 2% CGP46381 significantly inhibited the myopia (FDM + 2% CGP46381 versus FDM + saline, *P* \< 0.01). The lower dose of CGP46381 0.2% was not effective at inhibiting myopia (*P* \> 0.05).](BMRI2015-207312.001){#fig1}

![Effect of CGP46381 on axial length (AL). Interocular differences (mean ± SD) in AL varied significantly with treatment (*P* \< 0.0001). Compared to saline, 2% CGP46381 significantly inhibited the AL elongation (FDM + 2% CGP46381 versus FDM + saline, *P* \< 0.01). The lower dose of CGP46381 0.2% was not effective at inhibiting AL elongation (*P* \> 0.05).](BMRI2015-207312.002){#fig2}

![Effect of CGP46381 on vitreous chamber depth (VCD). Interocular differences (mean ± SD) in VCD varied significantly with treatment (*P* \< 0.0001). Compared to saline, 2% CGP46381 significantly inhibited the VCD elongation (FDM + 2% CGP46381 versus FDM + saline, *P* \< 0.01). The lower dose of CGP46381 0.2% was not effective at inhibiting the VCD elongation (*P* \> 0.05).](BMRI2015-207312.003){#fig3}
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